Labcorp stock reports 2026 growth targets amid reimbursement risk

Published on 09/28/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock closed at USD 309.64 on September 25, 2026, with a USD 25.4 billion market value. Q2 adjusted EPS reached USD 4.99 versus USD 4.78 consensus.

Aquarellbild eines gläsernen Bürogebäudes vor Skyline in Pastelltönen — Aquarellmalerei einer Stadtlandschaft mit gläsernem Firmensitz symbolisiert Labcorp, ISIN US50540R4092, im Gesundheitssektor, Illustration mit AI erstellt.

Labcorp stock (ISIN US50540R4092) closed at USD 309.64 on the NYSE on September 25, 2026, up 0.22 percent from the prior close. The latest policy catalyst is a preliminary Medicare reimbursement schedule that could reduce laboratory payment rates by up to 15 percent from 2027, as The Motley Fool reported on September 22, 2026.

2026 guidance stays quantified

At its September 10, 2026 Investor Day, Labcorp reaffirmed enterprise revenue guidance of USD 14.71 billion to USD 14.83 billion for fiscal year 2026.

The range implies growth of 5.40 percent to 6.30 percent versus 2025 revenue of USD 13.952 billion. Adjusted EPS guidance stands at USD 18.10 to USD 18.55, while free cash flow guidance is USD 1.24 billion to USD 1.36 billion.

Quarterly results beat consensus

Q2 2026 revenue reached USD 3.73 billion, up 5.80 percent year over year, while adjusted EPS was USD 4.99 against USD 4.78 consensus, according to MarketBeat on September 21, 2026.

That USD 0.21 adjusted EPS beat gives the growth targets a recent operating reference, although the reimbursement issue places greater weight on specialty testing, biopharma services and efficiency gains.

Reimbursement policy tests the outlook

The CMS proposal applies to 2027 through 2029, while Labcorp has reaffirmed its longer-term framework of 5.00 percent to 8.00 percent compound annual revenue growth through 2029. The company also targets adjusted EPS growth of 8.50 percent to 11.50 percent and adjusted operating margin expansion of 75 to 150 basis points by 2029.

For investors, the key tension is visible in the numbers: the latest quarter delivered USD 3.73 billion of revenue, but future payment rates could pressure the diagnostics business that underpins most of the 2026 revenue range.

Stock remains below the yearly high

Labcorp stock closed at USD 309.64 on September 25, 2026, with a market capitalization of USD 25.4 billion, volume of 816,334 shares and a 52-week range of USD 244.52 to USD 341.80. The closing price was 9.41 percent below the 52-week high.